AURKA and breast cancer: The Aurora-A/AURKA expression levels demonstrated independent prognostic impact also when adjusting for the traditional clinico-pathologic markers and molecular subtypes, also in the age group 40–49 years, as has been demonstrated in studies by others, but not specifically in young breast cancer cohorts [16, 44].